ES2684976T3 - Biomarcadores maternos para diabetes gestacional - Google Patents
Biomarcadores maternos para diabetes gestacional Download PDFInfo
- Publication number
- ES2684976T3 ES2684976T3 ES13775210.1T ES13775210T ES2684976T3 ES 2684976 T3 ES2684976 T3 ES 2684976T3 ES 13775210 T ES13775210 T ES 13775210T ES 2684976 T3 ES2684976 T3 ES 2684976T3
- Authority
- ES
- Spain
- Prior art keywords
- sample
- fibronectin
- glycosylated
- level
- psg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000004104 gestational diabetes Diseases 0.000 title claims abstract description 49
- 230000008774 maternal effect Effects 0.000 title description 38
- 239000000090 biomarker Substances 0.000 title description 9
- 238000000034 method Methods 0.000 claims abstract description 28
- 108010075433 glycosylated fibronectin Proteins 0.000 claims abstract description 14
- 238000000338 in vitro Methods 0.000 claims abstract 12
- 239000000523 sample Substances 0.000 claims description 64
- 210000002966 serum Anatomy 0.000 claims description 50
- 238000012360 testing method Methods 0.000 claims description 48
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 37
- 102100032752 C-reactive protein Human genes 0.000 claims description 31
- 108010003044 Placental Lactogen Proteins 0.000 claims description 30
- 239000000381 Placental Lactogen Substances 0.000 claims description 30
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 28
- 102000011690 Adiponectin Human genes 0.000 claims description 26
- 108010076365 Adiponectin Proteins 0.000 claims description 26
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 26
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 26
- 239000013074 reference sample Substances 0.000 claims description 22
- 101000617708 Homo sapiens Pregnancy-specific beta-1-glycoprotein 1 Proteins 0.000 claims description 18
- 102100022024 Pregnancy-specific beta-1-glycoprotein 1 Human genes 0.000 claims description 18
- 239000002523 lectin Substances 0.000 claims description 11
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 claims description 10
- 102100030758 Sex hormone-binding globulin Human genes 0.000 claims description 10
- 108090001090 Lectins Proteins 0.000 claims description 9
- 102000004856 Lectins Human genes 0.000 claims description 9
- 101600111816 Homo sapiens Sex hormone-binding globulin (isoform 1) Proteins 0.000 claims description 8
- 102300044179 Sex hormone-binding globulin isoform 1 Human genes 0.000 claims description 8
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 claims description 6
- 230000035945 sensitivity Effects 0.000 claims description 5
- 101000895818 Homo sapiens Chorionic somatomammotropin hormone 1 Proteins 0.000 claims description 3
- 101000956228 Homo sapiens Chorionic somatomammotropin hormone 2 Proteins 0.000 claims description 3
- 230000003169 placental effect Effects 0.000 claims description 3
- 238000012286 ELISA Assay Methods 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 108010041181 Aleuria aurantia lectin Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 description 77
- 108090000623 proteins and genes Proteins 0.000 description 77
- 208000037846 diffuse midline glioma Diseases 0.000 description 72
- 239000012491 analyte Substances 0.000 description 33
- 206010012601 diabetes mellitus Diseases 0.000 description 31
- 108010067306 Fibronectins Proteins 0.000 description 27
- 102000016359 Fibronectins Human genes 0.000 description 27
- 102000004576 Placental Lactogen Human genes 0.000 description 27
- 230000013595 glycosylation Effects 0.000 description 22
- 230000035935 pregnancy Effects 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 15
- 238000006206 glycosylation reaction Methods 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 238000003018 immunoassay Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 102000003886 Glycoproteins Human genes 0.000 description 10
- 108090000288 Glycoproteins Proteins 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 9
- 238000007410 oral glucose tolerance test Methods 0.000 description 9
- 238000012353 t test Methods 0.000 description 9
- 240000006028 Sambucus nigra Species 0.000 description 8
- 235000003142 Sambucus nigra Nutrition 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 235000008995 european elder Nutrition 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000002349 difference gel electrophoresis Methods 0.000 description 7
- 238000007477 logistic regression Methods 0.000 description 7
- 102000035122 glycosylated proteins Human genes 0.000 description 6
- 108091005608 glycosylated proteins Proteins 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 4
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000012125 lateral flow test Methods 0.000 description 4
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108010026552 Proteome Proteins 0.000 description 3
- 238000000546 chi-square test Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 102000057799 human ADIPOQ Human genes 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000001558 permutation test Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241000221688 Aleuria aurantia Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 206010025394 Macrosomia Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 108010005636 polypeptide C Proteins 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 101100387457 Arthrobacter globiformis dmg gene Proteins 0.000 description 1
- 208000021657 Birth injury Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010061452 Complication of pregnancy Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000018478 Foetal disease Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 101000942118 Homo sapiens C-reactive protein Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101000703436 Homo sapiens Sex hormone-binding globulin Proteins 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 206010036595 Premature delivery Diseases 0.000 description 1
- 206010040613 Shoulder Dystocia Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000003981 capillary liquid chromatography Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229940121538 choriogonadotropin beta Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000048863 human SHBG Human genes 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229920000592 inorganic polymer Polymers 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000010202 multivariate logistic regression analysis Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261623690P | 2012-04-13 | 2012-04-13 | |
| US201261623690P | 2012-04-13 | ||
| PCT/US2013/030152 WO2013154709A1 (en) | 2012-04-13 | 2013-03-11 | Maternal biomarkers for gestational diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2684976T3 true ES2684976T3 (es) | 2018-10-05 |
Family
ID=49325612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13775210.1T Active ES2684976T3 (es) | 2012-04-13 | 2013-03-11 | Biomarcadores maternos para diabetes gestacional |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US8852873B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2836845B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104380112B (cg-RX-API-DMAC7.html) |
| ES (1) | ES2684976T3 (cg-RX-API-DMAC7.html) |
| IN (1) | IN2014DN09410A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013154709A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160025737A1 (en) * | 2014-07-25 | 2016-01-28 | Diabetomics, Llc | Biomarkers for assessment of preeclampsia |
| WO2016153344A1 (en) * | 2015-03-20 | 2016-09-29 | Iq Products B.V. | Novel marker for gestational diabetes |
| CN106706928A (zh) * | 2017-01-19 | 2017-05-24 | 深圳大学 | 一种妊娠期糖尿病的早期预测标志物及其检测方法 |
| CN107024590A (zh) * | 2017-03-13 | 2017-08-08 | 新疆医科大学 | 一种诊断1型和2型糖尿病的血清蛋白标志物组 |
| CN113495150A (zh) * | 2020-03-19 | 2021-10-12 | 首都医科大学附属北京世纪坛医院 | 尿液白蛋白及其多肽片段在妊娠糖尿病中的应用 |
| CN113514634A (zh) * | 2020-04-09 | 2021-10-19 | 武汉市朗典精医生物科技有限公司 | 制备检测Adipo/SHBG双指标免疫层析试剂盒 |
| CN113804879A (zh) * | 2020-06-15 | 2021-12-17 | 北京康美天鸿生物科技有限公司 | 幽门螺旋杆菌IgM和IgG抗体联合检测试剂盒 |
| EP4428535A1 (en) * | 2023-03-09 | 2024-09-11 | Servizo Galego de Saude | Diagnosis, monitoring or prognosis of diabetes or prediabetes |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4855242A (en) | 1986-04-14 | 1989-08-08 | Joslin Diabetes Center, Inc. | Method of detecting antibodies |
| DE3800048A1 (de) | 1987-05-14 | 1988-11-24 | Boehringer Mannheim Gmbh | Verfahren zur bestimmung eines antikoerpers in menschlichen koerperfluessigkeiten |
| US5645998A (en) | 1988-12-13 | 1997-07-08 | University Of Florida Research Foundation | Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus |
| US5175085A (en) | 1990-02-20 | 1992-12-29 | Board Of Regents, The University Of Texas System | Methods and compositions for diagnosing autoimmune insulin dependent diabetes mellitus |
| DE69133393T2 (de) | 1990-09-07 | 2005-06-16 | The Regents Of The University Of California, Oakland | Verfahren zur diagnose und behandlung von diabetes |
| US5512447A (en) | 1990-09-07 | 1996-04-30 | The Regents Of The University Of California | Methods for the diagnosis and treatment of diabetes |
| US5674978A (en) | 1990-09-21 | 1997-10-07 | The Regents Of The University Of California | Peptides derived from glutamic acid decarboxylase |
| DE4129849A1 (de) | 1991-02-14 | 1992-08-27 | Boehringer Mannheim Gmbh | Monoklonale antikoerper gegen humane pankreas-inselzellen |
| JPH06508030A (ja) | 1991-05-15 | 1994-09-14 | ザイモジェネティクス，インコーポレイティド | ヒトすい島グルタミン酸デカルボキシラーゼ自己抗原のクローニング及び発現 |
| US5674692A (en) | 1991-09-06 | 1997-10-07 | Baekkeskov; Steinunn | Methods for diabetes susceptibility assessment in asymptomatic patients |
| US5200318A (en) | 1992-05-13 | 1993-04-06 | Miles Inc. | Diagnosis of IDDM with a panel of immunoreagents |
| WO1994012529A1 (en) | 1992-12-03 | 1994-06-09 | The Regents Of The University Of California | Improved reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome |
| ZA94845B (en) | 1993-02-09 | 1994-11-11 | Univ Monash | Methods for the diagnosis of diabetes and prediabetic conditions |
| ATE221200T1 (de) | 1993-04-16 | 2002-08-15 | Univ California | Verfahren zur bestimmung der diabetesanfälligkeit bei asymptomatischen patienten |
| US5547847A (en) | 1993-09-07 | 1996-08-20 | University Of Washington | Diagnosis of insulin-dependent diabetes |
| US5561049A (en) | 1994-09-21 | 1996-10-01 | Behringwerke Ag | Method for detecting antibodies |
| US5989551A (en) | 1995-10-25 | 1999-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Materials and methods for detection and treatment of insulin-dependent diabetes |
| US6391651B1 (en) | 1995-08-11 | 2002-05-21 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Materials and methods for detection of insulin dependent diabetes |
| US5821334A (en) | 1996-01-26 | 1998-10-13 | Vanderbilt University | Insulin-dependent diabetes mellitus-specific chimeric polypeptides |
| AU1989097A (en) | 1996-03-06 | 1997-09-22 | University Of Washington | Diabetes mellitus 37 kd autoantigen protein-tyrosine phosphatase |
| US5670377A (en) * | 1996-03-14 | 1997-09-23 | Sansum Medical Research Foundation | Method of diagnosing gestational diabetes |
| AUPO468597A0 (en) | 1997-01-21 | 1997-02-13 | Montech Medical Developments Pty Ltd | Expression in yeast of antigenically active, recombinant hybrid glutamic acid decarboxylase |
| US6303325B1 (en) | 1998-05-29 | 2001-10-16 | Dade Behring Inc. | Method for detecting analytes |
| DE19839736A1 (de) | 1998-09-01 | 2000-03-02 | Roche Diagnostics Gmbh | Humane monoklonale Antikörper gegen Inselzellantigen IA-2 |
| WO2002033408A1 (en) | 2000-10-17 | 2002-04-25 | Besst-Test Aps | Assay for directly detecting an inflammatory indicator in a body fluid sample |
| EP1386155A4 (en) | 2001-04-10 | 2006-05-10 | Univ Leland Stanford Junior | THERAPEUTIC AND DIAGNOSTIC USE OF ANTIBODY SPECIFICITY PROFILES |
| AU2003237312A1 (en) | 2002-05-29 | 2003-12-19 | University Of Washington | Mutants of gad65 and ian5 relating to diabetes |
| FR2847263B1 (fr) | 2002-11-18 | 2006-01-13 | Commissariat Energie Atomique | Polynucleotide specifique de la cellule pancreatique beta des ilots de langerhans |
| EP1631314B1 (en) | 2003-06-09 | 2011-08-03 | Redox-Reactive Reagents L.L.C. | Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions |
| US9557325B2 (en) | 2003-06-09 | 2017-01-31 | Redox-Reactive Reagents Llc | Method of altering the binding specificity of proteins by oxidation-reduction reactions |
| JP4717810B2 (ja) | 2003-06-20 | 2011-07-06 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド | １型糖尿病と２型糖尿病を識別するためのバイオマーカー |
| TW200508609A (en) | 2003-07-15 | 2005-03-01 | Bioarray Solutions Ltd | Detection of cell membrane-associated proteins using membrane fragments displayed on encoded microparticle arrays |
| WO2005017192A2 (en) | 2003-08-14 | 2005-02-24 | The General Hospital Corporation | Screening for gestational disorders |
| SE0400683D0 (sv) * | 2004-03-19 | 2004-03-19 | Forskarpatent I Syd Ab | Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis |
| US20060024757A1 (en) * | 2004-07-30 | 2006-02-02 | Robert Hussa | Detection of oncofetal fibronectin for selection of concepti |
| WO2006032126A1 (en) | 2004-09-24 | 2006-03-30 | Syn X Pharma, Inc. | Diagnosis and treatment of early pre-type-1 diabetes utilizing neuronal proteins |
| ITRM20050398A1 (it) | 2005-07-26 | 2007-01-27 | Gian Franco Bottazzo | Metodo per la rilevazione di cellule t in pazienti neodiagnosticati per diabete di tipo 1. |
| WO2007044396A2 (en) * | 2005-10-04 | 2007-04-19 | The Research Foundation Of State University Of New York | Fibronectin polypeptides and methods of use |
| WO2007062789A1 (en) | 2005-11-29 | 2007-06-07 | F. Hoffmann-La Roche Ag | Fibronectin as target/marker for insulin resistance |
| EP1989554A1 (en) | 2006-02-06 | 2008-11-12 | Rappaport Family Institute For Research in the Medical Sciences | Methods and kit for diagnosing t1dm |
| US20070224638A1 (en) | 2006-03-27 | 2007-09-27 | Institut Pasteur | Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections |
| EP2118309B1 (en) | 2006-12-29 | 2015-01-28 | The Regents of the University of Colorado, a body corporate | Diagnostic and therapeutic target for autoimmune diseases and uses thereof |
| WO2008102000A1 (en) | 2007-02-21 | 2008-08-28 | Sarl Endocells | Human pancreatic beta cell lines for diagnostic of diabetes |
| US20110052569A1 (en) | 2007-09-06 | 2011-03-03 | University Of Washington | Molecules and methods for treatment of diabetes |
| WO2009045403A2 (en) | 2007-10-01 | 2009-04-09 | The Board Of Trustees Of The Leland Stanford Junior University | MENIN REGULATION OF β-ISLET CELL PROLIFERATION |
| US20100017143A1 (en) * | 2008-01-30 | 2010-01-21 | Proteogenix, Inc. | Gestational age dependent proteomic changes of human maternal serum for monitoring maternal and fetal health |
| US20100016173A1 (en) * | 2008-01-30 | 2010-01-21 | Proteogenix, Inc. | Maternal serum biomarkers for detection of pre-eclampsia |
| US9176120B2 (en) | 2008-02-04 | 2015-11-03 | Women & Infants' Hospital Of Rhode Island | Serum-based, diagnostic, biological assay to predict pregnancy disorders |
| US8722343B2 (en) | 2008-11-21 | 2014-05-13 | Carla Perego | Methods and compositions for the diagnosis and treatment of diabetes |
| KR101067815B1 (ko) | 2009-02-05 | 2011-09-27 | 서울대학교산학협력단 | 제1형 당뇨병의 신규한 진단 마커 |
| US9939448B2 (en) | 2010-01-06 | 2018-04-10 | The Regents Of The University Of Colorado, A Body Corporate | Methods for detecting insulin autoantibody |
| WO2013025759A1 (en) | 2011-08-16 | 2013-02-21 | Battelle Memorial Institute | Peptide and protein biomarkers for type 1 diabetes mellitus |
-
2013
- 2013-03-11 IN IN9410DEN2014 patent/IN2014DN09410A/en unknown
- 2013-03-11 US US13/792,844 patent/US8852873B2/en active Active
- 2013-03-11 EP EP13775210.1A patent/EP2836845B1/en active Active
- 2013-03-11 CN CN201380031224.2A patent/CN104380112B/zh active Active
- 2013-03-11 ES ES13775210.1T patent/ES2684976T3/es active Active
- 2013-03-11 WO PCT/US2013/030152 patent/WO2013154709A1/en not_active Ceased
- 2013-11-21 US US14/085,974 patent/US8975034B2/en active Active
-
2014
- 2014-10-16 US US14/516,383 patent/US9383370B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20150037822A1 (en) | 2015-02-05 |
| US8852873B2 (en) | 2014-10-07 |
| EP2836845A4 (en) | 2015-11-18 |
| US8975034B2 (en) | 2015-03-10 |
| CN104380112A (zh) | 2015-02-25 |
| US20130274123A1 (en) | 2013-10-17 |
| IN2014DN09410A (cg-RX-API-DMAC7.html) | 2015-07-17 |
| CN104380112B (zh) | 2017-05-24 |
| EP2836845A1 (en) | 2015-02-18 |
| US20140080157A1 (en) | 2014-03-20 |
| US9383370B2 (en) | 2016-07-05 |
| EP2836845B1 (en) | 2018-05-09 |
| WO2013154709A1 (en) | 2013-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2684976T3 (es) | Biomarcadores maternos para diabetes gestacional | |
| WO2022083673A1 (zh) | 食管癌的生物标志物及其应用 | |
| ES2677944T3 (es) | Detección de infección intraamniótica | |
| ES2681238T3 (es) | Medios y métodos de aplicación de la relación sFlt-1/PIGF o Endoglina/PIGF para descartar la aparición de preeclampsia en un cierto periodo de tiempo | |
| CN105556308B (zh) | 用于阑尾炎的诊断和预后及腹痛病因的区分的方法和组合物 | |
| ES2650263T3 (es) | Dinámica de la razón de SFLT-1 o endoglina/PLGF como indicador para preeclampsia inminente y/o síndrome de HELLP | |
| US20220214365A1 (en) | Methods of Detecting Anti-folic acid Antibodies and Uses Thereof | |
| CN116298295B (zh) | 用于结直肠癌早期检测的肿瘤自身抗原/抗体组合及应用 | |
| US10996228B2 (en) | Biomarkers for assessment of preeclampsia | |
| CN116539885B (zh) | 用于乳腺癌早期检测的肿瘤自身抗原/抗体组合及应用 | |
| CN109313193B (zh) | 消化道癌的判定方法 | |
| US8697368B2 (en) | Diagnostic marker for lung cancer comprising HPαR as active ingredient | |
| US20150004633A1 (en) | Assays and methods for the diagnosis of ovarian cancer | |
| CN115372616A (zh) | 胃癌相关的生物标志物及其应用 | |
| CN116381237B (zh) | 一种甲状腺癌早期预测系统及其应用 | |
| CN116413430B (zh) | 一种用于肝癌早期预测的自身抗体/抗原组合及检测试剂盒 | |
| US20230375550A1 (en) | Method for diagnosing breast cancer by using biomarker | |
| KR20250145637A (ko) | 췌장암 검출 | |
| CN120334544A (zh) | 鼻咽癌抗体标志物及其应用 | |
| HK1240319A1 (en) | Biomarkers for assessment of preeclampsia |